



Pfizer Inc
275 North Field Drive
Lake Forest, IL 60045

August 2019

**Supply Available for
Heparin Sodium Injection, USP**

Dear Valued Customer,

Pfizer is committed to keeping you informed about supply availability as it relates to our Heparin presentations and wanted to take this opportunity to provide an update as it relates to the market landscape and the African Swine Fever (ASF) outbreak situation in China. Pfizer does not currently source the Active Pharmaceutical Ingredient (API) from China for its U.S. markets. Pfizer's current API inventory for the U.S. market allows us to continue manufacturing finished product and we have taken the following actions in anticipation of the market needs:

- Investigating opportunities to increase production with non-China based API
- Continue to supply diverse presentations in our portfolio
- Providing current historic demand allocations on certain presentations where needed to ensure we meet our contracted customers' demand
- Returning to market on other Heparin product presentations in Q3 2019

As a major provider of sterile injectables products, we will continue to monitor the market situation. We are keenly aware of the importance of Heparin to our hospital customers and their patients and will continue to keep you informed as new information becomes available.

To review the most up-to-date information on product availability, please download the Availability Report from our pfizerinjectables.com website. You can also contact our Supply Continuity Team between 7:00am – 6:00pm CT to discuss any product availability questions at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]).

Please reach out to your Pfizer Injectables sales representative or sales executive if you have any questions.

Thank you,

Anthony Ibrahim
Senior Portfolio Manager, Cardiovascular & Steroids
U.S. Hospital Business Unit

